Enzymatica publ AB Asset Resilience Ratio
Enzymatica publ AB asset resilience ratio. Enzymatica publ AB (ENZY) has an Asset Resilience Ratio of 22.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Enzymatica publ AB (ENZY) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Enzymatica publ AB (2020–2024)
Asset resilience ratio of Enzymatica publ AB from 2020 to 2024. This chart shows how Enzymatica publ AB's Asset Resilience Ratio has changed over time. Read ENZY current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Enzymatica publ AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ENZY asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr33.08 Million | 22.17% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr33.08 Million | 22.17% |
Asset Resilience Insights
- Good Liquidity Position: Enzymatica publ AB maintains a healthy 22.17% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Enzymatica publ AB Industry Peers by Asset Resilience Ratio
Compare Enzymatica publ AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Enzymatica publ AB Asset Resilience Ratio by Year (2020–2024)
Enzymatica publ AB asset resilience ratio by year from 2020 to 2024. The table below shows the annual Asset Resilience Ratio data for Enzymatica publ AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 38.53% | Skr75.21 Million ≈ $8.09 Million |
Skr195.22 Million ≈ $21.01 Million |
+31.88pp |
| 2023-12-31 | 6.64% | Skr8.37 Million ≈ $900.32K |
Skr125.91 Million ≈ $13.55 Million |
-22.42pp |
| 2022-12-31 | 29.06% | Skr50.69 Million ≈ $5.45 Million |
Skr174.41 Million ≈ $18.77 Million |
+8.93pp |
| 2021-12-31 | 20.13% | Skr31.62 Million ≈ $3.40 Million |
Skr157.04 Million ≈ $16.90 Million |
+5.31pp |
| 2020-12-31 | 14.82% | Skr24.02 Million ≈ $2.58 Million |
Skr162.03 Million ≈ $17.44 Million |
-- |
About Enzymatica publ AB
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.